Marker Therapeutics, Inc. MRKR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-69.5
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $3.5M | -$12.2M | — | — | $16.8M |
| 2024 | $6.6M | -$10.7M | — | — | $18.6M |
| 2023 | $3.3M | -$8.2M | — | — | $14.1M |
| 2022 | $3.5M | -$29.9M | — | — | $19.6M |
| 2021 | $1.2M | -$41.9M | — | — | $44.0M |
| 2020 | $500,000 | -$28.7M | — | — | $27.3M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -69.5 (distress)
- Working capital / assets 0.881
- Retained earnings / assets -24.077
- EBIT / assets -0.676
- Equity / liabilities 7.386
Source: SEC EDGAR filings · CIK 0001094038 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.